Why Are 70% Of Cancer Patients Unresponsive to Chemotherapy Treatments? (1241 hits)
Major discoveries in the cancer world are pointing toward more personalized methods for treating cancer, giving a better explanation and solution as to why only a small percentage of people respond satisfactorily to chemotherapy treatments. In this article, we'll explore the new science and important application of translational cancer genomics and epigenetics in a unique integrative medical setting...
Genetically Targeted Fractionated Chemotherapy
Most cancer clinics have a "one-size fits all" approach to cancers, but because each tumor is unique (based on specific genetics in the cancer itself, markers on the surface of cancer cells and epigenetic environment around the cancer cells toxins, infections, deficiencies and inflammation factors that cause cancers to spread and mutate) this approach fails to answer the bigger question.
That's where Genetically Targeted Fractionated Chemotherapy comes in. In short, GTFC is an advanced form of chemotherapy that applies molecular profiles, genetic typing and targeted treatment, providing patients with much needed alternatives. This method allows us to use multiple drugs in lower dosages to help reduce resistance, enhance targeting and improve overall treatment.
